GNMSF vs GILD: Which Stock is Better?

Side-by-side comparison of Genmab A/S and Gilead Sciences Inc in 2026

Comparison Updated:

GNMSF

Genmab A/S

$330.37

GILD

Gilead Sciences Inc

$124.14

Key Metrics Comparison

MetricGNMSFGILDWinner
Market Cap$20.35B$154.99BGILD
P/E Ratio14.4719.34GNMSF
EPS (TTM)$22.83$6.46GNMSF
Revenue Growth0.2%0.0%GNMSF
Gross Margin94.4%78.7%GNMSF

Analyze GNMSF

Full quant analysis

Analyze GILD

Full quant analysis

Analyze Each Stock

Frequently Asked Questions

Is GNMSF or GILD a better investment?

Comparing GNMSF and GILD: Genmab A/S has a market cap of $20.35B while Gilead Sciences Inc has $154.99B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.

What is the difference between GNMSF and GILD?

GNMSF (Genmab A/S) and GILD (Gilead Sciences Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.

Which stock has better value: GNMSF or GILD?

Based on P/E ratios, GNMSF trades at a lower multiple (14.5x vs 19.3x).

Which is growing faster: GNMSF or GILD?

GNMSF has higher revenue growth at 0.2% vs 0.0% for GILD.

Which company is more profitable: GNMSF or GILD?

Genmab A/S (GNMSF) has higher gross margins at 94.4% compared to 78.7% for GILD.

Which is the larger company: GNMSF or GILD?

Gilead Sciences Inc (GILD) is larger with a market cap of $154.99B compared to $20.35B for GNMSF.

Should I buy GNMSF or GILD in 2026?

Both GNMSF and GILD have investment merit. GNMSF trades at $330.37 while GILD trades at $124.14. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.

What are the key differences between GNMSF and GILD stock?

Key differences: Market Cap ($20.35B vs $154.99B), P/E Ratio (14.5x vs 19.3x), Revenue Growth (0.2% vs 0.0%), Gross Margin (94.4% vs 78.7%).

Popular Stock Comparisons